From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement
FROM THE EDITOR

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

News & Literature Highlights

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Transplantation and Cellular Therapy

Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Journal of Medical Cases

Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy

Clinical and Translational Oncology

Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology

World Journal of Oncology

Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome

Mayo Clinic Proceedings. Innovations, Quality, & Outcomes

Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective

Blood

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma

Transplantation and Cellular Therapy

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

Immunotherapy

The potential of phytomedicines to optimize CAR-T cell therapy in cancer

Advertisement
Advertisement